Based on the previous report on treatment of AD with Que from the perspective of the regulation of tau phosphorylation and inherited ability of Exo on targeting brain, we aimed at fabricating plasma derived Exo packed with quercetin (Exo-Que) to enhance drug bioavailability and achieve brain targeting in vivo. This evidence concerns the gene MAPT and Alzheimer disease.